Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

Bengt C Fellström, Alan G Jardine, Roland E Schmieder, Hallvard Holdaas, Kym Bannister, Jaap Beutler, Dong-Wan Chae, Alejandro Chevaile, Stuart M Cobbe, Carola Grönhagen-Riska, José J De Lima, Robert Lins, Gert Mayer, Alan W McMahon, Hans-Henrik Parving, Giuseppe Remuzzi, Ola Samuelsson, Sandor Sonkodi, D Sci, Gultekin SüleymanlarDimitrios Tsakiris, Vladimir Tesar, Vasil Todorov, Andrzej Wiecek, Rudolf P Wüthrich, Mattis Gottlow, Eva Johnsson, Faiez Zannad, AURORA Study Group, Alexander Maxwell

Research output: Contribution to journalArticle

1381 Citations (Scopus)

Abstract

Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved.
Original languageEnglish
Pages (from-to)1395-407
Number of pages13
JournalNew England Journal of Medicine
Volume360
Issue number14
DOIs
Publication statusPublished - 02 Apr 2009

Bibliographical note

AURORA study investigator

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Rosuvastatin and cardiovascular events in patients undergoing hemodialysis'. Together they form a unique fingerprint.

  • Cite this

    Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., De Lima, J. J., Lins, R., Mayer, G., McMahon, A. W., Parving, H-H., Remuzzi, G., Samuelsson, O., Sonkodi, S., Sci, D., ... Maxwell, A. (2009). Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine, 360(14), 1395-407. https://doi.org/10.1056/NEJMoa0810177